The FDA has not officially banned the compounding of enclomiphene, nor is there any news to suggest that this will take effect very soon. There was a vote conducted by PCAC regarding not including it in the bulks list, which has not been updated nor was it added to the "do not compound" list, and the FDA has yet to make a plan or date regarding any changes. As a result, compounding pharmacies are continuing to fulfill indefinitely until further notice.

Maximus will have additional treatment options for testosterone optimization available in the future, which are currently in the works, and we will discuss them publicly when they launch. No matter what happens in terms of regulation, we will be ready to work with our partners and patients to transition treatments and provide continuity of care.